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Abstract The main physiological role of somatostatin (SST) is
the control of hormone secretion. Recently, SST has been shown
to exert antiproliferative effects on some human tumors via both
direct and indirect mechanisms. We have previously found that in
the human neuroblastoma cell line SY5Y the SST analogue
lanreotide (BIM 23014) inhibited serum-stimulated cell prolif-
eration and MAP kinase activity. Here, we examine the effect of
SST on PDGF-induced Ras activation. We found that SST
suppressed PDGF-induced Ras activation in a pertussis toxin
(PTx)-independent and peroxovanadate-dependent manner. Ras-
specific GTPase activating protein (GAP) activities were not
altered by SST treatment. On the contrary, PDGF-induced
PDGF receptor phosphorylation was decreased by SST in a
PTx-independent, peroxovanadate-dependent manner, likely
accounting for the SST-mediated inhibition of PDGF-induced
Ras activation.
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1. Introduction
Somatostatin (SST) has a broad spectrum of biological ac-
tivities in di¡erent organ systems. The physiological role of
hypotalamic SST on GH and TSH secretion and on the reg-
ulation of pancreatic and gastrointestinal functions is well
established [1,2]. SST acts by interacting with speci¢c mem-
brane receptors. Five subtypes of human SST receptors
(hSSTR) have been recently cloned all belonging to the family
of G protein-coupled receptors with seven transmembrane
spanning domains (for a review see [3]).
Recently, the use of SST or the longer lasting analogues
octreotide and lanreotide to suppress cell proliferation of hu-
man tumors has been proposed [4,5]. Currently, the therapeu-
tic application of SST analogues is limited to neuroendocrine
tumors like carcinoids, GHomas, insulinomas, gastrinomas on
which these drugs are thought to act by inhibiting hormone
secretion. SST can inhibit secretion as well as tumor growth
both indirectly, via interference with growth factor produc-
tion, or directly, by interacting with speci¢c receptors on the
tumoral cells and possibly interfering with the mitogenic sig-
nalling. Finally, SST has been suggested to have antiangioge-
netic properties [6].
Most of the studies on SST were performed using ectopic
expression of SSTR and signal transducing molecules in cells
that normally do not express them. This raises the possibility
that non-physiological interactions might occur making di⁄-
cult to evaluate the relevance of the results obtained in such
manner. We therefore investigate the e¡ect of SST in a cell
system, the human neuroblastoma cells SY5Y, that endoge-
nously express SSTR [7]. We have previously shown that the
SST analogue lanreotide was able to inhibit cell proliferation
of SY5Y cells most likely by downregulating MAP kinase
activity [8]. To gain insight on the molecular mechanisms
responsible for the growth suppression of SY5Y cells and
MAP kinase inhibition by SST and its analogue, we investi-
gated the possibility that SST might act on and modulate
critical steps in the mitogenic signaling. The activation of
the small G protein Ras is a key event for the transmission
of the mitogenic signals triggered by activation of a variety of
growth factor receptors including platelet-derived growth fac-
tor receptors (PDGFR). PDGFR are expressed in SY5Y cells
[9]. We therefore set up to measure the e¡ect of SST on Ras
activation stimulated by PDGF by using a recently developed
functional Ras assay based upon the interaction of Ras-GTP
with a speci¢c Ras binding domain (RBD) on Raf-1 [10].
2. Materials and methods
2.1. Materials
PDGF-BB was from Boehringer Mannheim, Mannheim, Germany.
Peroxide of vanadate (peroxovanadate) was prepared by mixing van-
adate (Sigma Chemicals, St. Louis, MO, USA) with H2O2 (Merck,
Darmstadt, Germany) for 10 min at 37‡C. All reagents were pur-
chased from Sigma Chemicals, St. Louis, MO, USA unless otherwise
indicated.
2.2. Cell culture
SY5Y cells (kindly provided by Dr. D. Fornasari, Dept. of Phar-
macology, Milano, Italy) were routinely grown in RPMI-1640 me-
dium (Sigma Chemicals, St. Louis, MO, USA) supplemented with
10% heat-inactivated fetal bovine serum (FBS, Gibco, Grand Island,
NY, USA). Mouse ¢broblasts (kindly donated by Dr. T. Pawson,
Dept. of Molecular and Medical Genetics, Toronto, Ont., Canada)
were grown in DMEM medium (Sigma Chemicals, St. Louis, MO,
USA) supplemented with 10% FBS. All cell lines were kept at 37‡C in
a humidi¢ed atmosphere of 5% CO2 in air.
2.3. Ras activity assay
Gst-RBD (aa 51^131 of Raf-1) fusion protein was isolated in our
laboratory from pGEX 2T-RBD induced with IPTG as previously
described [10]. Activated Ras-GTP was precipitated from whole cell
lysates (prepared in lysis bu¡er containing 50 mM HEPES, pH 7.4;
250 mM NaCl; 5 mM MgCl2 ; 10% glycerol; 1% Triton X-100;
0.5 mM phenylmethylsulfonyl £uoride (PMSF); 10 Wg/ml leupeptin
and 10 Wg/ml aprotinin) with 20 Wl glutation agarose beads coupled
with Gst fusion protein containing the Ras binding domain (RBD) of
Raf. After 12% SDS-PAGE, active Ras protein was detected by West-
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ern blotting using monoclonal anti-Ras antibodies (Transduction
Laboratories, Lexington, KY, USA).
2.4. GAP assay on cell lysates
Cell lysates were prepared using a lysis bu¡er containing 25 mM
Tris-HCl pH 7.5; 100 mM NaCl; 1% NP-40; 1% glycerol; 10 mM
MgCl2 ; 1 mM dithiothreitol (DTT); 1 mM Na3VO4 ; 0.5 mM PMSF;
10 Wg/ml leupeptin and 10 Wg/ml aprotinin. The puri¢ed Ras protein
(500 ng), kindly provided by Dr. M. Vanoni (Dept. of General Phys-
iology and Biochemistry, Dept. of Biology, Milano, Italy), was loaded
with 1 WM [Q-32P]GTP as described [11]. The Ras-GTP complex
(50 ng) was incubated with cell lysates (100 Wg) or lysis bu¡er at
room temperature in GAP bu¡er (25 mM Tris-HCl pH 7.5;
100 mM NaCl; 10 mM MgCl2 ; 1 mg/ml BSA; 2 mM GTP;
0.1 mM DTT). At intervals, aliquots were removed and the GAP
activity was determined by measuring the amount of protein-bound
radioactive GTP remaining on the ¢lter, by liquid scintillation count-
ing. The results are expressed as the amount of cpm of non-hydro-
lyzed GTP remaining on the ¢lters. Background counts were less than
2% of total bound [Q-32P]GTP. Each time point was measured in
triplicate and the values are expressed as the mean þ S.E.M.
2.5. MAP kinase activity assay
Quiescent SY5Y cells, plated in 60 mm diameter Petri dishes, were
washed with phosphate-bu¡ered saline (PBS) and lysed in 600 Wl of
lysis bu¡er containing 50 mM Tris-HCl, pH 7.5; 100 mM NaCl;
5 mM EDTA; 1 mM DTT; 40 mM Na4P2O7 ; 0.2 mM Na3VO4 ;
1% Triton X-100; 1 mM PMSF; 10 Wg/ml aprotinin; 10 Wg/ml leu-
peptin and 10 Wg/ml pepstatin. After a 15 min centrifugation at
13 000Ug at 4‡C, MAP kinase was immunoprecipitated from the
lysates using a polyclonal anti-ERK 2 antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and protein A-Sepharose beads. Im-
munocomplex kinase assay was performed for 30 min at 30‡C in
kinase bu¡er (containing 40 mM HEPES-NaOH, pH 7.5; 5 mM
magnesium acetate; 2 mM DTT; 1 mM EGTA; 0.2 mM Na3VO4 ;
1 mM PMSF; 10 Wg/ml aprotinin; 10 Wg/ml leupeptin and 10 Wg/ml
pepstatin) using myelin basic protein (250 Wg/ml, MBP, Gibco BRL,
Grand Island, NY, USA) and [Q-32P]ATP (3.0 WCi/sample; speci¢c
activity 3000 Ci/mmol; Amersham, UK) as substrates. An aliquot
of the supernatants was transferred onto P81 phosphocellulose paper
squares and after ¢ve washes in 0.75% phosphoric acid the radioac-
tivity associated to the squares was determined by liquid scintillation
counting.
2.6. Immunoprecipitation and immunoblotting
Quiescent SY5Y cells, plated in 100 mm diameter Petri dishes, were
washed with PBS and lysed in 500 Wl of lysis bu¡er containing 50 mM
Tris-HCl, pH 7.4; 150 mM NaCl; 1 mM EGTA; 1% NP-40; 0.25%
sodium deoxycholate; 1 mM Na3VO4 ; 1 mM NaF; 1 mM PMSF;
10 Wg/ml aprotinin; 10 Wg/ml leupeptin and 10 Wg/ml pepstatin. After
a 20 min incubation at 4‡C, the lysate was collected and centrifuged at
13 000Ug for 10 min at 4‡C. Proteins of interest were immunopreci-
pitated using a polyclonal anti-PDGF receptor antibody (Upstate
Biotechnology, Lake Placid, NY, USA) or a monoclonal anti-phos-
photyrosine antibody (PY20, Transduction Laboratories, Lexington,
KY, USA). The immunocomplexes were separated by 7.5% SDS-
PAGE, transferred on nitrocellulose membranes and the ¢lters incu-
bated with the appropriate antibodies. The immunoreactive bands
were then detected by ECL system (Amersham, UK).
2.7. Densitometric analysis
The densitometric analysis of the immunoblots was performed us-
ing the NIH Image 1.44 program. Each blot was analyzed by a single
operator that was unaware of treatment groups. Data are expressed as
mean þ S.D. of the percentage of inhibition measured in SST plus
PDGF-treated samples versus PDGF-treated samples, considered as
100%.
3. Results
Serum-deprived SY5Y cells were stimulated with 20 ng/ml
of PDGF with or without pretreatment with SST (10 nM).
Total cellular lysates were immunoprecipitated with Gst-RBD
(the minimal Ras binding domain of Raf) which preferentially
binds to the GTP-bound active form of Ras. As shown in Fig.
1A, PDGF stimulation of cells (lane 2) increased the amount
of active Ras bound to Gst-RBD relative to the amount of
activated Ras present in lysates of untreated cells (lane 1).
Pretreatment of SY5Y cells with SST abrogated almost com-
pletely the formation of Ras-GTP induced by PDGF (lane 3).
Densitometric analysis of the immunoblots showed an inhi-
bition of 61.1 þ 18.4% (n = 6) caused by SST which had no
e¡ect on unstimulated Ras activity (lane 4). Equal amount
of total Ras proteins were subjected to the RBD binding assay
as shown by immunoblotting of an aliquot of the same lysates
used for the assay followed by detection with anti-Ras anti-
bodies (Fig. 1A, lower panel). The reduction in the level of
activated Ras was paralleled by an inhibition of 44.0 þ 2.96%
(n = 3), of PDGF-induced MAP kinase activity as measured
by immunocomplex kinase assay (Fig. 1B), in agreement with
our previous data [8].
The biological e¡ects of SST are mediated through a family
of G protein-coupled receptors of which ¢ve members have
been identi¢ed by molecular cloning [3]. All ¢ve hSSTRs are
functionally coupled to inhibition of adenylate cyclase via
PTx-sensitive GTP binding proteins [12]. In SY5Y cells pre-
treated for 4 h with PTx (100 ng/ml), SST was still capable of
inhibiting PDGF-induced Ras activation (Fig. 2A). The e⁄-
Fig. 1. E¡ect of SST on PDGF-induced Ras and MAP kinase acti-
vation. A: Serum-deprived SY5Y cells were pretreated for 8 min
with SST (10 nM) and then stimulated with PDGF-BB (20 ng/ml)
for 4 min before cell lysis. Ras was identi¢ed either by a⁄nity pre-
cipitation with Gst-RBD followed by immunoblotting (upper panel)
or by immunoblotting of total cell lysates (lower panel) using anti-
Ras antibodies. This experiment was repeated six times with similar
results. B: Serum-deprived SY5Y cells were treated as above with
medium alone (open bar), PDGF (vertical bar) or SST and PDGF
(cross-hatched bar). MAP kinase activity was measured by immuno-
complex kinase assay as described in Section 2. Data are expressed
as cpm of 32P incorporated in MBP and are the mean þ S.E.M. of
three independent experiments, each performed in duplicate.
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cacy of the toxin in these cells is demonstrated by the shift of
the ADP ribosylated GKi1 and Ki2 subunits caused by the 4 h
treatment with PTx (Fig. 2A, insert). These data indicate that
the coupling of the SST receptor to the e¡ector responsible for
the inhibitory action on Ras does not occur via a PTx-sensi-
tive G protein raising the possibility that SST might act
through coupling of SSTR to a PTx-resistant G protein. In-
deed, a PTx-resistant GK12 subunit was shown to be capable
of reducing the amount of Ras-GTP stimulated by EGF in
COS-7 cells by activating the Ras GPTase activating protein
Gap1m [13]. This ¢nding prompted us to assess whether SST-
dependent inhibition of Ras activation could be due to the
ability of SST to modulate Ras-speci¢c GAP activities. To
measure GAP activities, a recombinantly produced and puri-
¢ed Ras protein was loaded with [Q-32P]GTP and incubated
with total cellular lysates obtained from SY5Y cells. As shown
in Fig. 3A, the addition of cellular lysates increased the rate of
GTP hydrolysis as compared to the addition of lysis bu¡er
alone as a control. However, no di¡erences in GAP activity
could be observed in lysates obtained from SY5Y cells
whether or not PDGF or SST or a combination of the two
were used to treat the cells. This was not due to the inability
of the assay to detect di¡erences in GAP activities as demon-
strated by GAP assays performed on total cellular lysates
derived from ¢broblasts in which the Ras-GAP gene was ge-
netically removed [14]. As shown in Fig. 3B, the rate of hy-
drolysis of GTP-loaded Ras of lysates from Ras-GAP 3/3
cells was substantially decreased when compared to the one
measured in lysates from wild-type ¢broblasts. Thus, activa-
tion of a Ras-speci¢c GAP is unlikely to be responsible for the
observed SST-dependent, PTx-independent inhibition of Ras
activation.
Individual subtypes of SSTR have been shown to be linked
to multiple transmembrane e¡ectors other than adenylate cy-
clase. For example, SST has been shown to stimulate a tyro-
sine phosphatase activity [15^18] which appears to be respon-
sible for SST-mediated antiproliferative e¡ect [16^18]. To test
whether a tyrosine phosphatase activity is involved in the in-
hibitory e¡ect of SST on Ras activation, we pretreated the
cells with peroxovanadate, an inhibitor of tyrosine phospha-
tase activity (for a review see [19]). As shown in Fig. 2B,
peroxovanadate reverted the inhibitory e¡ect of SST on
PDGF-induced Ras activity, suggesting that the activity of a
protein tyrosine phosphatase is involved in the SST e¡ect.
Fig. 2. E¡ect of Pertussis toxin and sodium peroxovanadate treat-
ment on SST-induced inhibition of Ras activity stimulated by
PDGF. A: Where indicated, serum-deprived SY5Y cells were prein-
cubated for 4 h with PTx (100 ng/ml) prior to assay. Cells pre-
treated with SST (10 nM) for 8 min were then stimulated with
PDGF-BB (20 ng/ml) for 4 min. Ras was identi¢ed in cell lysates as
described in Fig. 1A. This experiment was repeated 12 times with
similar results. In the insert, the shift of the ADP-ribosylated Ki1
and Ki2 G protein subunits following PTx pretreatment is presented.
B: Serum-deprived SY5Y cells were pretreated with sodium peroxo-
vanadate (25 WM) for 10 min where indicated. Prior to stimulation
with PDGF-BB (20 ng/ml) for 4 min, the cells were treated with
SST (10 nM) for 8 min. Ras was identi¢ed in cell lysates as de-
scribed in Fig. 1A. This experiment was repeated ¢ve times with
similar results.
Fig. 3. E¡ect of SST on Ras-speci¢c GAP activities in SY5Y cells
and Ras-Gap1 +/+ and 3/3 mouse ¢broblasts. A: Puri¢ed Ras
protein was loaded with [Q-32P]GTP. The Ras-GTP complex was in-
cubated with 100 Wg of total cellular lysates obtained from serum-
deprived SY5Y cells that were either untreated (a) or treated with
SST (10 nM) (O) or PDGF-BB (20 ng/ml) (b), or SST and PDGF
(R). Controls were performed with lysis bu¡er alone (F). B: GAP
activity was measured by incubating the Ras-GTP complex with 100
Wg of total cellular lysates obtained from wild-type (b) or Ras-GAP
3/3 (a) ¢broblasts. Controls were performed as in A (F). At the
indicated time points, aliquots were subjected to ¢lter binding as-
says, as described in Section 2. The GAP activity is expressed as to-
tal cpm of non-hydrolyzed [Q-32P]GTP which remained bound on
the ¢lters. Values are the mean þ S.E.M. of three independent ex-
periments each performed in triplicate.
FEBS 22659 22-9-99
M.G. Cattaneo et al./FEBS Letters 459 (1999) 64^6866
Peroxovanadate per se slightly increased active Ras (lane 4).
We then analyzed the level of protein phosphorylation in-
duced by PDGF in presence of SST pretreatment. Quiescent
SY5Y cells were treated with PDGF for 2 min with or without
SST pretreatment. Total cellular lysates were subjected to im-
munoprecipitation either with anti-phosphotyrosine (P-Tyr)
or anti-PDGF receptor (PDGF-R) antibodies (Fig. 4A,B
and C). The immunoprecipitates were then resolved by 7.5%
SDS-PAGE and examined by immunoblotting with anti-P-
Tyr antibody. As shown in Fig. 4A and B, a prominent
band of apparent molecular weight of 180 kDa appeared ty-
rosine phosphorylated upon PDGF stimulation. Pretreatment
with SST decreased the phosphorylation of the 180 kDa band
by 40.0 þ 17.2% (n = 11) as determined by densitometric anal-
ysis (Fig. 4A and B, three ¢rst lanes). To assess whether the
band of 180 kDa corresponds to the PDGF receptor itself, we
immunoprecipitated PDGF receptor with anti-PDGFR-spe-
ci¢c antibodies and looked at its phosphorylation levels
upon pretreatment with SST followed by PDGF stimulation.
As shown in Fig. 4C, the phosphorylation of PDGFR induced
by PDGF was decreased by 48.0 þ 5.9% (n = 5) following pre-
treatment with SST. Western blotting with anti-PDGFR anti-
body of an aliquot of the total cellular lysates (Fig. 4A and B,
lower panel) and of the immunoprecipitates (Fig. 4C, lower
panel) showed that equal amounts of proteins were present in
all the samples. We then examined the phosphorylation levels
of PDGF receptor with or without SST pretreatment in cells
that were incubated for 4 h with PTx (100 ng/ml). As shown
in Fig. 4A, SST inhibited PDGF-induced PDGF receptor
phosphorylation also in the presence of Ptx. Conversely, van-
adate pretreatment reversed the inhibitory e¡ect of SST on
PDGF receptor phosphorylation (Fig. 4B). Thus, the inhibi-
tory e¡ect of SST on PDGF receptor phosphorylation is PTx-
insensitive and vanadate-sensitive similarly to the hormone
inhibitory e¡ect on Ras.
4. Discussion
The present study was undertaken to gain insight into the
molecular mechanism of SST inhibition of growth factor-de-
pendent cell proliferation in SY5Y neuroblastoma cells. Ras
plays a key role in the transduction of mitogenic signals by
external stimuli, including polypeptide growth factors like
PDGF. Here, we show that SST inhibits PDGF-induced
Ras activation in human neuroblastoma cells. Gi-coupled re-
ceptors have been shown to activate Ras via a mechanism that
involves the LQ subunits of the Gi protein [20]. Our results
show for the ¢rst time that a Gi-coupled receptor may instead
inhibit Ras activity. The inhibition by SST on Ras is not
sensitive to PTx raising the possibility that SST acts by cou-
pling SSTR to PTx-insensitive Gi protein. All ¢ve hSST re-
ceptors cloned are coupled to a variety of intracellular signals
including the inhibition of adenylate cyclase and L-type cal-
cium channel and the activation of K channels all of which
are mediated by PTx-sensitive G proteins. Recently, however,
the PTx-insensitive G protein subunit K12 has been shown to
directly bind and activate one of the Ras-GTPase activating
proteins, GAP1m, and thus negatively regulates Ras signalling
in COS cells [13]. A similar mechanism, however, does not
seem to account for the observed SST-dependent inhibition
of Ras activation since SST has no e¡ect on Ras-speci¢c GAP
activities measured in total cellular lysates of SY5Y cells.
An alternative possible mechanism of action given the PTx-
insensitivity of the SST e¡ect, is the direct association of
SSTR to a downstream e¡ector molecule by-passing the re-
quirement for coupling of SSTR to G proteins. Recently, the
Fig. 4. E¡ect of SST on the PDGF receptor phosphorylation. Ly-
sates from SY5Y cells stimulated for 2 min with PDGF-BB (20 ng/
ml) with or without pretreatment with SST (10 nM) were subjected
to immunoprecipitation with anti-phosphotyrosine (A, B) or anti-
PDGF receptor (C) antibodies. Immunoprecipitates were resolved
by 7.5% SDS-PAGE and analyzed by immunoblotting with the indi-
cated antibody. A Western blot of the PDGFR in an aliquot of the
total cell lysates (A and B) or of the immunoprecipitates (C) is pre-
sented under each experiment. In A and B cells were also pretreated
with PTx (100 ng/ml for 4 h) or peroxovanadate (25 WM for 10 min)
respectively before exposure to SST and PDGF. Cell lysates were
subjected to immunoprecipitation with anti-phosphotyrosine anti-
bodies and the immunoprecipitates were analyzed as described
above. Each type of experiment was repeated ¢ve times with similar
results.
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Na/H exchanger was shown to be regulated by the L2 adre-
nergic receptor via an intermediate protein bearing a PDZ
domain which binds to a consensus sequence on the C-termi-
nal tail of the receptor [21]. The same consensus sequence (T/
SXV/L/I) is present on the C-terminal tail of all the SSTR
subtypes with the exception of the SSTR4. This raises the
possibility that SST inhibition of Ras activation might be
mediated by the association of the receptor with a protein
bearing a PDZ domain acting either directly as an e¡ector
or indirectly as an adapter molecule. The identi¢cation of
such a molecule would allow to test its involvement in SST
inhibition of PDGF-induced Ras activation and e¡orts in this
direction are actually ongoing in our laboratory.
Peroxovanadate treatment of cells abrogates the inhibitory
e¡ect of SST on PDGF-stimulated Ras activity suggesting
that a tyrosine phosphatase might be involved in mediating
SST action. That a tyrosine phosphatase could be the SST
e¡ector is further supported by the inhibition of the PDGFR
tyrosine phosphorylation caused by SST. The reduction in the
receptor phosphorylation level may hamper or reduce the
downstream signaling leading to Ras activation. To identify
such phosphatase and the nature of its coupling to the SST
receptor will be instrumental in de¢ning novel molecular
mechanisms underlying not only the SST action, but also
the cross-talk between receptor tyrosine kinases and heptahel-
ical receptor-mediated signaling networks.
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